Skip to content
Contactez-nous: (+33) 1 64 62 10 12
Theradiag
  • Home
  • Company
    • About us
    • Our history
    • A word from our CEO
    • Our management team
    • Board of directors
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics – TRACKER
      • Therapeutic Drug Monitoring of Biologics
        • TDM of Biologics
        • When to perform TDM ?
        • Results interpretation
        • Therapeutic Thresholds
        • Tracker Publications
        • Guidelines
        • Frequently asked questions
      • TRACKER
        • LISA TRACKER
        • I-Tracker
        • i-Track 10
        • Immunotrol Tracker
    • Patient Stratification -PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • SARS-CoV 2 Serology Testing
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English
Menu Close

Analyst coverage

  1. Home>
  2. Investors>
  3. Shareholder information>
  4. Analyst coverage

Analysts covering Theradiag :

  • SWISSLIFE BioStrategic Research – Lionel Labourdette
  • PORTZAMPARC – Christophe Dombu

You can access the latest research notes published (only available in French) :

THERADIAG Flash Portzamparc 12.01.2021

THERADIAG Flash Portzamparc 12.01.2021

THERADIAG Flash Portzamparc 22.07.2020

THERADIAG Flash SwissLife 22.07.2020

THERADIAG Flash SwissLife 23.04.2020

THERADIAG Flash SwissLife 20.03.2020

THERADIAG Flash Portzamparc 31.01.2020

THERADIAG Flash SwissLife 31.01.2020

THERADIAG Flash SwissLife  11.12.2019

THERADIAG Flash SwissLife 25.09.2019

THERADIAG Flash SwissLife 19.07.2019 

THERADIAG Flash Portzamparc 19.07.2019

THERADIAG Flash Portzamparc 02.04.2019

Latest Press Releases

  • 30/03/2022 Evolution of governance
    30 March 2022/
    0 Comments
  • Presentation of the 2021 full year results (only available in french) – 2022, 21st March
    21 March 2022/
    0 Comments
  • 21/03/2022: Theradiag announces its 2021 full-year results
    21 March 2022/
    0 Comments

Events

02 Apr 2022

21st Annual GI Update

19 - 20 May 2022

Annual congress BIO MED J

Palais des Congrès d’Issy les Moulineaux
19 - 20 May 2022

Annual congress BIO MED J

Palais des Congrès d’Issy les Moulineaux
No event found!
Load More

Next financial Event

No event found!

Useful links

  • Diagnostic
  • Theranostic
  • Events
  • Register to receive our latests news

Contact Information

  • Address:14, Rue Ambroise Croizat, 77183 Croissy Beaubourg, France
  • Phone:+33 1 64 62 10 12
  • Email:info@theradiag.comOpens in your application

Follow Us

Theradiag ©
  • Home
  • Company
    • About us
    • Our history
    • A word from our CEO
    • Our management team
    • Board of directors
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics – TRACKER
      • Therapeutic Drug Monitoring of Biologics
        • TDM of Biologics
        • When to perform TDM ?
        • Results interpretation
        • Therapeutic Thresholds
        • Tracker Publications
        • Guidelines
        • Frequently asked questions
      • TRACKER
        • LISA TRACKER
        • I-Tracker
        • i-Track 10
        • Immunotrol Tracker
    • Patient Stratification -PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • SARS-CoV 2 Serology Testing
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English
We use cookies to ensure the best experience on our website. If you continue to use this site, we will assume that you are satisfied.OkNoLearn more